Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients
Status:
Completed
Trial end date:
2021-04-20
Target enrollment:
Participant gender:
Summary
Fute (Flupentixol) combined with MARTAs (Multiple-Acting Receptor Targeted Antipsychotics)
drugs has its clinical efficacy toward positive symptoms and might reduce the metabolic
syndrome-related factors in patients. This study is the first clinical trial to explore the
treatment of patients with flupentixol combined with MARTAs. However, due to research
limitations, the number of patients who participated in the clinical trial is small, and it
depends on subsequent larger-scale clinical trials for more in-depth verification.